ArticleCell death & disease2026
HPC restores mitochondrial homeostasis and ameliorates hypoxic stress through the GSK-3β/β-catenin signaling pathway.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hypoxic preconditioning (HPC) can increase the hypoxia tolerance of the mouse hippocampus both in vivo and in vitro by upregulating ATP levels, which may depend on mitochondrial homeostasis. The GSK-3β/β-catenin signaling pathway is involved in neuroprotection after brain ischemia. The aim of this study was to explore whether HPC can activate GSK-3β/β-catenin to improve the hypoxia tolerance of neuronal cells by enhancing mitochondrial homeostasis. In vitro and in vivo analyses revealed that HPC upregulates the activity of the GSK-3β/β-catenin pathway, maintaining mitochondrial morphological stability. Mechanistically, GSK-3β activity is negatively correlated with mitochondrial homeostasis. Pharmacological inhibition of GSK-3β reduced mitochondrial fission, whereas HPC suppressed GSK-3β expression to attenuate fission and preserve mitochondrial integrity. Conversely, GSK-3β overexpression abrogated HPC-mediated protection and exacerbated mitochondrial dysfunction. These findings elucidate a neuroprotective mechanism whereby HPC stabilizes mitochondrial dynamics via modulation of the GSK-3β/β-catenin pathway, providing novel experimental insights into HPC-mediated neuroprotection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.